Review Opinions of the Compensation and Assessment Committee on the Company's Second Employee Stock Ownership Plan and 2026 Stock Option Incentive Plan
Pro Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") Ninth Board of Directors Compensation and Assessment Committee has conducted a thorough review of the second employee stock ownership plan and the 2026 stock option incentive plan in accordance with the Company Law of the People's Republic of China (hereinafter referred to as "the Company Law"), the Securities Law of the People's Republic of China (hereinafter referred to as "the Securities Law"), the Guidance on Pilot Implementation of Employee Stock Ownership Plans by Listed Companies (hereinafter referred to as "the Guidance"), the Management Measures for Equity Incentives of Listed Companies (hereinafter referred to as "the Management Measures"), the Self-Regulatory Guidelines No. 1 for Listed Companies on the Shenzhen Stock Exchange (hereinafter referred to as "Self-Regulatory Guidelines No. 1"), and other relevant laws, regulations, normative documents, and the Articles of Association of Pro Pharmaceutical Co., Ltd. (hereinafter referred to as "the Articles of Association"). The opinions are as follows: